ArticleBreast care (Basel, Switzerland)2024

Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Nadia Harbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.